AlloVir

Rank#10331

Market Cap1.91M

CountryUnited States

Summary

Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108. The company was formerly known as ViraCyte, Inc. and changed its name to Allovir, Inc. in May 2019. Allovir, Inc. was founded in 2013 and is based in Waltham, Massachusetts.

History

AlloVir was founded in 2013 as an early-stage biotechnology company focused on the development and commercialization of novel viral reduction technologies for organ transplants. It was founded by Dr. Paul Bergman and Dr. Barry Diamond and is headquartered in San Francisco, CA.

Mission

Our mission is to develop effective, affordable, lifesaving transplant therapies through delivery of innovative viral reduction therapies

Vision

To become a global leader in the field of transplant therapies by improving safety, efficacy and affordability of virus-free transplants.

References

https://www.investing.com/equities/allovir-inc

https://www.comparably.com/companies/vision/mission

https://www.crunchbase.com/organization/viracyte

https://finance.yahoo.com/quote/alvr/

https://www.allovir.com

https://sec.report/CIK/0001754068

Leadership team